GlassScriptPhysician profile
George W Williams
NPI 1679511455
$3,848.53
in general payments reported to CMS, 2019-2025
27 companies · $15.93 in 2025
The $15.93 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $417 · 2021: $1,141 · 2022: $816 · 2023: $582 · 2024: $115 · 2025: $15.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.44 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,157.10 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $839.53 | 2019-2024 | Liletta, Orilissa, Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $303.02 | 2019-2023 | |
| Astellas Pharma US INC | $228.17 | 2020-2023 | Veozah, Myrbetriq |
| Currax Pharmaceuticals LLC | $153.32 | 2022-2024 | Contrave, Onzetra Xsail |
| Allergan, INC. | $144.28 | 2019 | |
| Therapeuticsmd, INC. | $125.25 | 2019-2022 | |
| Glaxosmithkline, LLC. | $123.12 | 2021 | |
| Medtronic, INC. | $107.27 | 2022-2023 | Resparray |
| Mayne Pharma Commercial LLC | $78.04 | 2021-2022 | |
| Exeltis, USA INC. | $77.75 | 2021-2025 | Slynd |
| Idorsia Pharmaceuticals US INC | $68.71 | 2022-2023 | Quviviq |
| Hologic Sales and Service, LLC | $61.37 | 2021-2023 | Aptima |
| Pfizer INC. | $50.07 | 2019-2022 | |
| Amgen INC. | $47.15 | 2019-2023 | Prolia, Evenity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $43.88 | 2022-2023 | Accrufer |
| Roche Diagnostics Corporation | $41.47 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $40.95 | 2019 | |
| Amag Pharmaceuticals, INC. | $25.72 | 2019 | |
| Duchesnay USA Incorporated | $24.99 | 2019 | |
| Lilly USA, LLC | $22.85 | 2024 | Zepbound |
| Pacira Pharmaceuticals Incorporated | $18.77 | 2022 | |
| Boston Scientific Corporation | $14.79 | 2023 | Solyx Sis System |
| Kvk-Tech, INC. | $14.47 | 2019 | |
| Organon LLC | $12.53 | 2023-2024 | Nexplanon |
| Avion Pharmaceuticals | $12.31 | 2019 | |
| Becton, Dickinson and Company | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.